Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients

Brings Eversense 365 to the growing community of iLet Bionic Pancreas users

Plan for commercial launch of the integrated system in Q4 2026

GERMANTOWN, Md., Sept. 14, 2026 (GLOBE NEWSWIRE) — Senseonics Holdings, Inc. (NASDAQ: SENS), maker of the Eversense 365 Continuous Glucose Monitoring (CGM) System, the world’s first and only long-term, one-year implantable sensing technology, today announced a partnership with Beta Bionics, Inc (NASDAQ: BBNX), a pioneering leader in the development of advanced diabetes management solutions. The companies are collaborating to integrate Eversense® 365 CGM with Beta Bionics’ iLet® Bionic Pancreas automated insulin delivery (AID) system designed to simplify diabetes management. The integrated device will aim to provide people with diabetes a world-class, truly differentiated AID experience, combining year-long, exceptionally accurate glucose sensing1 with fully adaptive insulin delivery technology that does not require carb counting* and autonomously determines and delivers user insulin doses.

Eversense 365’s unique implantable design, consistent performance over an entire year2, and reduced device burden make it well-suited for AID systems, helping users focus less on their diabetes management technology and more on living their lives — and giving even more people with diabetes the freedom to choose the AID experience that best fits their lives.

“Our Eversense 365 is redefining the CGM market with long-term implantable technology designed to empower better diabetes management and reduce device burden. This collaboration with Beta Bionics will expand our reach to a greater population of people to enable them to manage their diabetes with the most advanced technologies available today,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. “We are excited to be working with Beta Bionics on integrating Eversense 365 with the iLet Bionic Pancreas to give more people with diabetes a differentiated AID option and greater choice in finding the experience that is right for them. Building on the early success from our first pump integration, we believe the combination of year-long glucose sensing and advanced automated insulin delivery offers compelling, differentiated benefits for people with diabetes and expands the choices available to them within the AID category.”

Senseonics expects development of the Eversense 365-iLet integration to be completed during the fourth quarter of 2026. Commercial launch is planned following completion of integration activities in the fourth quarter of 2026, subject to required testing, validation activities and applicable regulatory requirements.

Individuals interested in learning more about the integrated Eversense 365 and iLet system, including information on early access opportunities, can sign up to receive updates.

*User must be carb aware.

About Senseonics
Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the design, development and commercialization of glucose monitoring products to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM system Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.

For more information, visit www.senseonics.com.

About Eversense® 365
The Eversense Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and up to 180 days for Eversense E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 14 for Eversense 365 and one time per day after day 21 for Eversense E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more.

For important safety information, see https://www.eversensediabetes.com/safety-info/.

Forward Looking Statements

Any statements in this press release about the expectations regarding potential impact on, benefits to, experience of, expanded options for, or outcomes for people with diabetes’ and providers’, statements regarding the results, success and timeline for completion or commercial launch of the integration, statements regarding product’s reach or market impact, and other statements containing the words “believe,” “expect,” “intend,” “may,” “projects,” “will,” “planned,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the new product launch and ongoing commercialization of Eversense 365, uncertainties inherent in the coordination with third parties and new partners and joint work to complete the project, uncertainties inherent in the development of new technologies, uncertainties in insurer, regulatory and administrative processes and decisions, uncertainties in prescriber and patient decisions and responses to new technology or initiatives, and such other factors as are set forth in the risk factors detailed in Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent quarterly reports on Form 10-Q filed with the SEC under the heading “Risk Factors.” In addition, the forward-looking statements included in this press release represent Senseonics’ views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.

Senseonics Media Contact
Tim Stamper
FTI Consulting
Tim.Stamper@senseonics.com / Senseonics@fticonsulting.com

Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com

______________________
1 Senseonics. (2026) Eversense 365 Continuous Glucose Monitoring System User Guide. LBL-7702-01-001
2 Kaufman F, Jain I, Han S, Mdigini C: Real-World Data from U.S. Commercial Users of the 365-Day Implantable Eversense Continuous Glucose Monitoring System, Including with the twiist AID System Integration. Diabetes Technology & Therapeutics, 8 September 2026; https://doi.org/10.1177/15209156261486125

Board to recommend that shareholders approve renaming the Company Milk Makeup plc

  • The Company’s Board of Directors has approved the voluntary delisting of the Company’s Class A Ordinary Shares and Warrants from Nasdaq and the deregistration of those securities under the Exchange Act.
  • Company expects to file a Form 25 with the SEC on or about September 24, 2026; delisting expected to become effective on or about October 4, 2026, with the last day of trading on Nasdaq expected to be October 2, 2026.
  • Following completion of the sale of Obagi Medical, Waldencast is a single-brand company; shareholders will be asked at an Extraordinary General Meeting to approve renaming the Company Milk Makeup plc. If approved, the Company intends to seek to have its Class A Ordinary Shares quoted in an over-the-counter market under a new ticker symbol “MLKM”.

LONDON, Sept. 14, 2026 (GLOBE NEWSWIRE) — Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”) today announced that it has notified the Nasdaq Stock Market LLC (“Nasdaq”) of its decision to voluntarily delist its Class A ordinary shares, par value $0.0001 per share (the “Class A Ordinary Shares”), and its redeemable warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share (the “Warrants”), from Nasdaq and to deregister such securities under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

The Company intends to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the “SEC”) to remove its Class A Ordinary Shares and Warrants from listing on Nasdaq on or about September 24, 2026, and as a result, Waldencast expects that the last trading day of its Class A Ordinary Shares and Warrants on Nasdaq will be on or about October 2, 2026. Thereafter, on or about October 5, 2026, the Company intends to file a Form 15 (Certification and Notice of Termination of Registration) with the SEC to suspend the Company’s reporting obligations under Sections 12(g) and 15(d) of the Exchange Act. Upon filing of the Form 15, the Company’s obligation to file periodic reports with the SEC, including Annual Reports on Form 20-F and Current Reports on Form 6-K, will be suspended immediately. The Section 12(b) deregistration is expected to become effective 90 days after the Form 25 filing.

The decision to delist and deregister the Class A Ordinary Shares and Warrants was approved by the Board of Directors of the Company (the “Board”) following an evaluation of a range of factors, including, among others:

  • The direct and indirect costs of maintaining a Nasdaq listing and U.S. public reporting status (including audit, legal, advisory, insurance, transfer agent and compliance costs), which have become disproportionate to the size of the Company following the divestiture of Obagi Medical.
  • The substantial demands that public company reporting, including compliance with Section 404 of the Sarbanes-Oxley Act, places on senior management’s time and on the Company’s finance organization – time the Board believes is better directed to building the Milk Makeup brand.
  • The limited trading volume in, and limited public float of, the Company’s Class A Ordinary Shares, and the concentration of the Company’s share register, which the Board believes have not delivered the liquidity, research coverage or valuation benefits that a public listing is intended to provide.
  • The Board’s assessment that the Company’s capital structure and financing needs no longer depend on access to the U.S. public equity markets following the full debt paydown with the proceeds from the Obagi Japan trademark sale and the Obagi Medical divestiture.
  • The alternatives available to the Company and the Board’s conclusion that the expected cost savings and operational focus outweigh the reduction in liquidity and public information that will result. In the year ended December 31, 2025, the Company incurred central headquarters costs of $18.5 million. The Board expects that a substantial portion of those costs will be eliminated following the delisting and deregistration.

The Board considered the interests of all shareholders, including minority holders, in reaching this decision, and consulted with its financial and legal advisors.

Subject to shareholder approval, the Board has resolved to recommend that the Company be renamed Milk Makeup plc, so that the corporate identity of the Company aligns with its sole operating brand following completion of the sale of Obagi Medical. A change of name requires approval by special resolution under the Company’s Articles of Association and Jersey law. The Company intends to convene an Extraordinary General Meeting in the coming weeks, and a notice of meeting and accompanying materials will be made available to shareholders in accordance with the Company’s Articles of Association. The delisting and deregistration described above are not conditional on approval of the change of name, and the Company intends to proceed on the timetable set out in this announcement regardless of the outcome of the vote.

Following the delisting of the Company’s Class A Ordinary Shares and Warrants from trading on Nasdaq, the Company intends to seek to have its Class A Ordinary Shares quoted in an over-the-counter market under the ticker “MLKM”, where it intends to publish annual audited financial statements. There is no guarantee, however, that trading of the Company’s Class A Ordinary Shares will occur in an over-the-counter market or otherwise.

Separately, any further allocation of transaction proceeds from the sale of Obagi Medical to Bridgepoint, completed on July 30, 2026, remains subject to review by the Board.

The Company reserves the right to postpone or withdraw the above filings prior to their effectiveness; if necessary, the Company will make any further announcements as required by the Nasdaq listing standards and other applicable laws.

The Company expects to publish a trading update for the six months ended June 30, 2026, and comparable periods in the coming weeks.

About Waldencast

Waldencast plc (NASDAQ: WALD) is the parent company of Milk Makeup, the clean prestige beauty brand born from the creative community of Milk Studios in downtown New York City. Founded in 2016, Milk Makeup is built on the values of self-expression and inclusion, captured by its signature “Live Your Look,” and creates vegan, cruelty-free, clean formulas across a portfolio of hero franchises. Milk Makeup is available through milkmakeup.com and retail partners including Sephora, Ulta Beauty and Amazon Premium Beauty in the U.S., and select retailers internationally. For more information, please visit: www.milkmakeup.com.

Forward-Looking Statements

Statements in this release that are not historical are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the Company’s intention to delist from Nasdaq and to deregister from the SEC, the intended benefits of the delisting and deregistration, the intended rebranding of the business, the allocation of transaction proceeds from the sale of Obagi Medical and future strategies that may be pursued by the Company. These forward-looking statements generally are identified by the words “intends,” “may,” “will,” “future,” “expects,” “anticipates,” “believes,” “seeks,” “targets” and variations of these words or similar expressions (or the negative versions of such words or expressions) and are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the Company, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include, but are not limited to: (1) the inability to recognize the anticipated benefits of the delisting and deregistration, including the possibility that the cost savings the Board currently expects are not realized in whole or in part, or are realized more slowly or in lesser amounts than expected; (2) the general impact of geopolitical events, including the impact of current wars, conflicts and other hostilities; (3) the overall economic and market conditions and other information about the Company’s possible or assumed future results of operations or performance; (4) changes in general economic conditions; (5) the impact of any international trade or foreign exchange restrictions, the imposition of new or increased tariffs, and foreign currency exchange fluctuations; (6) the ability to implement the Company’s strategic initiatives and continue to innovate its existing products and anticipate and respond to market trends and changes in consumer preferences; (7) the possibility that the Form 25 or the Form 15 is not filed, or does not become effective, on the expected timetable, or that the SEC denies or delays the deregistration; (8) the possibility that no market maker quotes the Class A Ordinary Shares following the delisting, and the resulting reduction in liquidity and in publicly available information regarding the Company; (9) the ability to obtain shareholder approval for the proposed rebranding and to successfully implement the rebranding of the business; and (10) the outcome of the Board’s review of the allocation of transaction proceeds from the sale of Obagi Medical. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on March 13, 2026, or in other documents that may be filed or furnished by the Company from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Waldencast Contact

Investors ICR Allison Malkin waldencastir@icrinc.com

Media ICR Brittany Fraser waldencastpr@icrinc.com

JERICHO, N.Y., Sept. 14, 2026 (GLOBE NEWSWIRE) — Kimco Realty® (NYSE: KIM) announced today that its management will present at the BofA Securities 2026 Global Real Estate Conference on Tuesday, September 15, 2026.

Event: Kimco Realty® Management Presentation

When: Tuesday, September 15, 2026, from 12:45 PM – 1:20 PM, ET

Live Webcast: Kimco Realty Management to Present at the BofA Securities 2026 Global Real Estate Conference

Audio from the conference will be available on Kimco Realty’s investor relations website until December 15, 2026.

About Kimco Realty®

Kimco Realty® (NYSE: KIM) is a real estate investment trust (REIT) and leading owner and operator of high-quality, open-air, grocery-anchored shopping centers and mixed-use properties in the United States. The company’s portfolio is strategically concentrated in the first-ring suburbs of the top major metropolitan markets, including high-barrier-to-entry coastal markets and Sun Belt cities. Its tenant mix is focused on essential, necessity-based goods and services that drive multiple shopping trips per week. Publicly traded on the NYSE since 1991 and included in the S&P 500 Index, the company has specialized in shopping center ownership, management, acquisitions, and value-enhancing redevelopment activities for more than 65 years. With a proven commitment to corporate responsibility, Kimco Realty is a recognized industry leader in this area. As of June 30, 2026, the company owned interests in 564 U.S. shopping centers and mixed-use assets comprising 100 million square feet of gross leasable space.

The company announces material information to its investors using the company’s investor relations website (investors.kimcorealty.com), SEC filings, press releases, public conference calls, and webcasts. The company also uses social media to communicate with its investors and the public, and the information the company posts on social media may be deemed material information. Therefore, the company encourages investors, the media, and others interested in the company to review the information that it posts on the social media channels, including Facebook (www.facebook.com/KimcoRealty), and LinkedIn (www.linkedin.com/company/kimco-realty-corporation). The list of social media channels that the company uses may be updated on its investor relations website from time to time.

CONTACT:
David F. Bujnicki
Senior Vice President, Investor Relations and Strategy
Kimco Realty Corporation
(833) 800-4343
dbujnicki@kimcorealty.com

Net cash provided by operations increased by approximately 250% year-over-year in fiscal 2026

HOBOKEN, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) — The Hain Celestial Group, Inc. (Nasdaq: HAIN) (“Hain” or the “Company”), a leading global health and wellness company whose purpose is to inspire healthier living through better-for-you brands, today reported financial results for its fiscal fourth quarter and fiscal year ended June 30, 2026. In a separate press release issued today, the Company announced it has reached a definitive agreement to sell its International business.

“Fiscal 2026 was a pivotal year for Hain. We simplified our portfolio, reduced debt, significantly improved free cash flow and exited the year with improving momentum across the business. Our fourth quarter results reflected encouraging sequential improvement, including organic net sales growth in North America, gross margin and adjusted EBITDA margin expansion, and continued progress on productivity and cost discipline initiatives,” stated Alison Lewis, President and CEO.

Lewis continued, “Assuming we successfully complete the transaction announced today to sell our International business and that we reach an agreement with our lenders to extend of our December debt maturity, we would expect to become a more focused North American company with leading brands in attractive categories and a streamlined operating model.”

FINANCIAL HIGHLIGHTS*

Summary of Fiscal Fourth Quarter Results Compared to the Prior Year Period

  • Net sales were $263 million, down 28% year-over-year, driven primarily by the divestiture of our North American snacks business.
    • Organic net sales decreased 2% compared to the prior year period.
      • The decrease in organic net sales was comprised of a 2-point decrease in volume/mix and flat pricing.
  • Gross profit margin was 22.5%, a 200-basis point increase from the prior year period.
    • Adjusted gross profit margin was 22.7%, a 230-basis point increase from the prior year period.
  • Net loss was $62 million, compared to a net loss of $273 million in the prior year period.
    • Adjusted net loss was $4 million, compared to adjusted net loss of $2 million in the prior year period.
  • Adjusted EBITDA was $19 million, compared to $20 million in the prior year period.
  • Loss per diluted share was $0.68, compared to a loss per diluted share of $3.06 in the prior year period.
    • Adjusted loss per diluted share was $0.05, compared to adjusted loss per diluted share of $0.02 in the prior year period.

Summary of Fiscal Year 2026 Results Compared to the Prior Year

  • Net sales were $1,353 million, down 13% year-over-year.
    • Organic net sales decreased 3% compared to the prior year.
      • The decrease in organic net sales was comprised of a 3-point decrease in volume/mix, partially offset by a 1-point increase in pricing.
  • Gross profit margin was 20.1%, a 130-basis point decrease from the prior year.
    • Adjusted gross profit margin was 20.5%, a 100-basis point decrease from the prior year.
  • Net loss was $305 million, compared to a net loss of $531 million in the prior year.
    • Adjusted net loss was $16 million, compared to adjusted net income of $8 million in the prior year.
  • Adjusted EBITDA was $89 million, compared to $114 million in the prior year.
  • Loss per diluted share was $3.36, compared to a loss per diluted share of $5.89 in the prior year.
    • Adjusted loss per diluted share was $0.17, compared to adjusted earnings per diluted share of $0.09 in the prior year.

Cash Flow and Balance Sheet Highlights

  • Net cash provided by operating activities was $11 million in the fiscal fourth quarter, compared to net cash used in operating activities of $3 million in the prior year period; net cash provided by operating activities was $78 million in fiscal 2026 compared to $22 million in the prior year.
  • Free cash flow was $7 million in the fiscal fourth quarter, compared to an outflow of $9 million in the prior year period; free cash flow was $58 million in fiscal 2026 compared to an outflow of $3 million in the prior year.
  • Total debt was $558 million at the end of the fiscal fourth quarter, down from $705 million at the beginning of the fiscal year.
  • Net debt was $500 million at the end of the fiscal fourth quarter, compared to $650 million at the beginning of the fiscal year.
  • The company ended the fiscal fourth quarter with a net secured leverage ratio of 4.5x as calculated under our credit agreement.

____________________ 
*This press release includes certain non-GAAP financial measures, which are intended to supplement, not substitute for, comparable GAAP financial measures. Reconciliations of non-GAAP financial measures to GAAP financial measures and other non-GAAP financial calculations are provided in the tables included in this press release.

SEGMENT HIGHLIGHTS 

The company operates under two reportable segments: North America and International.

  Net Sales
  Q4 FY26 Q4 FY26 YTD
  $ Millions Reported
Growth Y/Y
M&A/Exit
Impact1
FX Impact Organic
Growth Y/Y
$ Millions Reported
Growth Y/Y
M&A/Exit
Impact1
FX Impact Organic
Growth Y/Y
North America 112 -46% -47% -0% 2% 685 -23% -23% 0% 0%
International 151 -4% -1% 1% -4% 668 -0% -0% 4% -4%
                     
Total 263 -28% -26% 0% -2% 1,353 -13% -13% 2% -3%
* May not add due to rounding
1 Reflects the impact within reported net sales growth of the following items that are excluded from organic net sales growth: net sales from divested brands (ParmCrisps®, Garden Veggie Snacks™, Terra® chips and Garden of Eatin’® snacks brands), held for sale businesses (Personal Care), discontinued brands, and exited product categories.
                     

North America
Fiscal fourth quarter organic net sales increased by 2% year-over-year, primarily driven by growth in meal prep on strength in yogurt, partially offset by lower sales in baby & kids.

Segment gross profit was $34 million and adjusted gross profit was $35 million in the fiscal fourth quarter, representing decreases of 14% and 12%, respectively, from the prior year period. Gross margin was 30.6% and adjusted gross margin was 31.1%, representing increases of 1,140 and 1,190 basis points, respectively, from the prior year period. The increases in margin were primarily driven by an increase in volume / mix and productivity savings, partially offset by cost inflation.

Adjusted EBITDA in the fiscal fourth quarter was $16 million, an increase of 55% compared to the prior year period. The increase was driven primarily by SG&A reduction and productivity savings, partially offset by lower volume/mix and cost inflation. Adjusted EBITDA margin was 14.4% of net sales, a 940-basis point increase compared to the prior year period.

Fiscal 2026 organic net sales were effectively flat year-over-year, as growth in meal prep and beverages was offset by lower sales in baby & kids.

Segment gross profit was $157 million and adjusted gross profit was $162 million in fiscal 2026, representing decreases of 19% and 17%, respectively, from the prior year. Gross margin was 22.9% and adjusted gross margin was 23.7%, representing increases of 120 and 180 basis points, respectively, from the prior year. The increases in margin were primarily driven by productivity savings and pricing, partially offset by cost inflation.

Adjusted EBITDA in fiscal 2026 was $61 million, a decrease of 7% compared to the prior year. The decrease was driven primarily by lower volume / mix and cost inflation, partially offset by productivity savings, reduction in SG&A, and pricing. Adjusted EBITDA margin was 8.9% of net sales, a 160-basis point increase compared to the prior year.

International
Fiscal fourth quarter organic net sales decreased by 4% year-over-year, primarily driven by lower sales in meal prep and baby & kids, partially offset by growth in beverages.

Segment gross profit and adjusted gross profit in the fiscal fourth quarter were both $25 million, each representing a 28% decrease from the prior year period. Gross margin and adjusted gross margin were both 16.6%, each representing a 555-basis point decrease from the prior year period. The decreases in margin were primarily driven by cost inflation, partially offset by productivity savings.

Adjusted EBITDA in the fiscal fourth quarter was $12 million, compared to $21 million in the prior year period, a decrease of 41%. The decrease was primarily driven by cost inflation and lower volume/mix, partially offset by productivity savings. Adjusted EBITDA margin was 8.1% compared to 13.3% in the prior year period.

Fiscal 2026 organic net sales decreased by 4% year-over-year, primarily driven by lower sales in baby & kids and meal prep.

Segment gross profit and adjusted gross profit in fiscal 2026 were both $115 million, each representing an 18% decrease from the prior year. Gross margin and adjusted gross margin were both 17.2%, each representing a 380-basis point decrease from the prior year. The decreases in margin were primarily driven by cost inflation, partially offset by productivity savings.

Adjusted EBITDA in fiscal 2026 was $63 million, compared to $86 million in the prior year, a decrease of 26%. The decrease was primarily driven by cost inflation and lower volume / mix, partially offset by productivity savings and pricing. Adjusted EBITDA margin was 9.5% compared to 12.8% in the prior year.

CATEGORY HIGHLIGHTS

  Net Sales
  Q4 FY26 Q4 FY26 YTD
  $ Millions Reported
Growth Y/Y
M&A/Exit
Impact1
FX Impact Organic
Growth Y/Y
$ Millions Reported
Growth Y/Y
M&A/Exit
Impact1
FX Impact Organic
Growth Y/Y
Baby & Kids 52 -12% -1% 0% -11% 215 -11% -1% 2% -12%
Beverages 55 -1% 0% 1% -2% 256 4% -0% 4% 1%
Meal Prep 135 -4% -7% 0% 3% 620 -3% -5% 3% 0%
Snacks 9 -91% -84% 0% -7% 213 -43% -36% 0% -7%
Personal Care 12 -19% n/a n/a n/a 49 -21% n/a n/a n/a
                     
Total 263 -28% -26% 0% -2% 1,353 -13% -13% 2% -3%
* May not add due to rounding
1 Reflects the impact within reported net sales growth of the following items that are excluded from organic net sales growth: net sales from divested brands (ParmCrisps®, Garden Veggie Snacks™, Terra® chips and Garden of Eatin’® snacks brands), held for sale businesses (Personal Care), discontinued brands, and exited product categories.
                     

Baby & Kids
The fiscal fourth quarter organic net sales decline of 11% year-over-year was driven primarily by formula and purees in North America and purees in the UK, partially offset by growth in finger foods in North America.

The fiscal 2026 organic net sales decline of 12% year-over-year was driven primarily by purees in both regions and by formula in North America, partially offset by growth in finger foods and cereal in North America.

Beverages
The fiscal fourth quarter organic net sales decline of 2% year-over-year was due to promotional activity in North America. Fiscal fourth quarter organic net sales grew 3% year-over-year in both tea in North America and in private label non-dairy beverage in Europe.

Fiscal 2026 organic net sales increased by 1% year-over-year driven by tea in North America and private label non-dairy beverage in Europe, partially offset by branded non-dairy beverage in Europe.

Meal Prep
Fiscal fourth quarter organic net sales increased by 3% year-over-year driven primarily by growth in yogurt in North America.

Fiscal 2026 organic net sales were flat year-over-year as growth in yogurt in North America was offset by private label contract losses in spreads & drizzles and softness in plant-based meat internationally.

Snacks
Following the disposition of the North American snacks business, the snacks category is comprised of jellies in the International segment. Organic net sales declined 7% year-over-year in both the fiscal fourth quarter and fiscal 2026.

Conference Call and Webcast Information

Hain Celestial will host a conference call and webcast today at 8:00 AM ET to discuss its results. The live webcast and accompanying presentation are available under the Investors section of the company’s corporate website at www.hain.com. Investors and analysts can access the live call by dialing 833-461-5787 or 585-542-9983. The conference ID is 942039942. Participation by the press and public in the Q&A session will be in listen-only mode. A webcast replay of the call will be available shortly after the conclusion of the live call and archived for one year.

About The Hain Celestial Group, Inc.

Hain Celestial is a leading global health and wellness company whose purpose is to inspire healthier living for people, communities and the planet through better-for-you brands. For more than 30 years, Hain Celestial has intentionally focused on delivering nutrition and well-being that positively impacts today and tomorrow. Headquartered in Hoboken, N.J., Hain Celestial’s products across beverages, yogurt, baby/kids and meal preparation are marketed and sold around the world. Our leading brands include Celestial Seasonings® teas, The Greek Gods® yogurt, Earth’s Best® Organic and Ella’s Kitchen® baby and kids foods, Joya® and Natumi® plant-based beverages, Hartley’s® jelly, as well as Cully & Sully®, Yorkshire Provender®, New Covent Garden® soups, among others. For more information, visit www.hain.com and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward-looking statements. The words “believe,” “expect,” “anticipate,” “may,” “should,” “plan,” “intend,” “potential,” “will” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, among other things, our beliefs or expectations relating to our future performance, results of operations and financial condition; and our strategic initiatives and business strategy, including the pending sale of our International business.

Risks and uncertainties that may cause actual results to differ materially from forward-looking statements include: compliance with our credit agreement and our ability to refinance, retire and/or extend the maturity of our existing debt; our ability to execute our business strategy; our ability to complete the pending sale of our International business and manage the challenges and uncertainty facing our remaining business following the sale; challenges and uncertainty resulting from the impact of competition; changes to consumer preferences; our ability to manage our supply chain effectively; input cost inflation, including as a result of tariffs; reliance on independent contract manufacturers; disruption of operations at our manufacturing facilities; customer concentration; reliance on independent distributors; risks associated with operating internationally; risks associated with outsourcing arrangements; risks associated with geopolitical conflicts or events; our reliance on independent certification for a number of our products; our ability to attract and retain highly skilled people; risks related to tax matters; foreign currency exchange risk; general economic conditions; impairments in the carrying value of goodwill or other intangible assets; the reputation of our company and our brands; our ability to use and protect trademarks; cybersecurity incidents; disruptions to information technology systems; pending and future litigation, including litigation relating to Earth’s Best® baby food products; potential liability if our products cause illness or physical harm; the highly regulated environment in which we operate; compliance with data privacy laws; the adequacy of our insurance coverage; climate impacts; liabilities, claims or regulatory change with respect to environmental matters; the potential cessation of our common stock’s listing on The Nasdaq Stock Market LLC; and other risks and matters described in our most recent Annual Report on Form 10-K, our Annual Report on Form 10-K expected to be filed today and our other filings from time to time with the U.S. Securities and Exchange Commission.

We undertake no obligation to update forward-looking statements to reflect actual results or changes in assumptions or circumstances, except as required by applicable law.

Non-GAAP Financial Measures

This press release and the accompanying tables include non-GAAP financial measures, including, among others, organic net sales; adjusted gross profit and its related margin; adjusted operating income and its related margin; adjusted net (loss) income and its related margin; diluted net (loss) income per common share, as adjusted; adjusted EBITDA and its related margin; free cash flow; and net debt. The reconciliations of historic non-GAAP financial measures to the comparable GAAP financial measures are provided in the tables below. These non-GAAP financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures. In addition, these non-GAAP measures may not be the same as similar measures provided by other companies due to potential differences in methods of calculation and items being excluded. They should be read only in connection with the company’s consolidated financial statements presented in accordance with GAAP.

We define our non-GAAP financial measures as follows:

  • Organic net sales: net sales excluding the impact of acquisitions, divestitures, held for sale businesses, discontinued brands, exited product categories and foreign exchange. To adjust organic net sales for the impact of acquisitions, the net sales of an acquired business are excluded from fiscal quarters constituting or falling within the current period and prior period where the applicable fiscal quarter in the prior period did not include the acquired business for the entire quarter. To adjust organic net sales for the impact of divestitures, held for sale businesses, discontinued brands and exited product categories, the net sales of a divested business, held for sale business, discontinued brand or exited product category are excluded from all periods. To adjust organic net sales for the impact of foreign exchange, current period net sales for entities reporting in currencies other than the U.S. dollar are translated into U.S. dollars at the average monthly exchange rates in effect during the corresponding period of the prior fiscal year, rather than at the actual average monthly exchange rate in effect during the current period of the current fiscal year.
  • Adjusted gross profit and its related margin: gross profit, before plant closure related costs, net and warehouse and manufacturing consolidation and other costs, net.
  • Adjusted operating income and its related margin: operating loss before goodwill impairment, costs associated with acquisitions, divestitures and other transactions, productivity and transformation costs, certain litigation expenses, net, long-lived asset and intangibles impairment, plant closure related costs, net, proceeds from insurance claim, CEO succession costs, warehouse and manufacturing consolidation and other costs, net.
  • Adjusted net (loss) income and its related margin and diluted net (loss) income per common share, as adjusted: net loss, adjusted to exclude the impact of goodwill impairment, costs associated with acquisitions, divestitures and other transactions, productivity and transformation costs, certain litigation expenses, net, long-lived asset and intangibles impairment, plant closure related costs, net, proceeds from insurance claim, CEO succession costs, warehouse and manufacturing consolidation and other costs, net , unrealized currency losses, loss (gain) on sales of assets, and the related tax effects of such adjustments.
  • Adjusted EBITDA and its related margin: net loss before depreciation and amortization, equity in net loss of equity-method investees, net interest expense, income taxes, stock-based compensation, net, unrealized currency losses, certain litigation expenses, net, proceeds from insurance claim, productivity and transformation costs, plant closure related costs, net, warehouse and manufacturing consolidation and other costs, net, CEO succession costs, costs associated with acquisitions, divestitures and other transactions, loss (gain) on sales of assets, goodwill impairment and long-lived asset and intangibles impairment. 
  • Free cash flow: net cash provided by (used in) operating activities less purchases of property, plant and equipment.
  • Net debt: total debt less cash and cash equivalents.

We believe that the non-GAAP financial measures presented provide useful additional information to investors about current trends in the company’s operations and are useful for period-over-period comparisons of operations. We provide:

  • Organic net sales to demonstrate the growth rate of net sales excluding the impact of acquisitions, divestitures, held for sale businesses, discontinued brands, and exited product categories and foreign exchange, and believe organic net sales is useful to investors because it enables them to better understand the growth of our business from period to period.
  • Adjusted results as important supplemental measures of our performance and believe they are frequently used by securities analysts, investors and other interested parties in the evaluation of our Company and companies in our industry.
  • Free cash flow as one factor in evaluating the amount of cash available for discretionary investments.
  • Net debt as a useful measure to monitor leverage and evaluate the balance sheet.

We discuss the Company’s net secured leverage ratio as calculated under our credit agreement as a measure of our financial condition, liquidity and compliance with our credit agreement. For a description of the material terms of our credit agreement and risks of non-compliance with our credit agreement, see “Liquidity and Capital Resources” under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” in our most recent Annual Report on Form 10-K, our subsequent Quarterly Reports on Form 10-Q, our Annual Report on Form 10-K expected to be filed today and our other filings from time to time with the U.S. Securities and Exchange Commission.

Investor Relations Contact:
Alexis Tessier
Investor.Relations@hain.com

Media Contact:
Justin Godley
Justin.Godley@hain.com

 
THE HAIN CELESTIAL GROUP, INC. AND SUBSIDIARIES
Consolidated Statements of Operations
(unaudited and in thousands, except per share amounts)
               
  Fourth Quarter   Fourth Quarter Year to Date
  2026   2025   2026   2025
               
Net sales $ 263,069     $ 363,348     $ 1,353,429     $ 1,559,780  
Cost of sales   203,866       289,002       1,081,317       1,225,722  
Gross profit   59,203       74,346       272,112       334,058  
Selling, general and administrative expenses   62,546       67,416       248,039       271,833  
Goodwill impairment   42,293       227,364       193,219       428,882  
Amortization of acquired intangible assets   5,077       1,300       10,802       6,476  
Productivity and transformation costs   4,520       5,033       22,039       21,530  
Long-lived asset and intangibles impairment   430       24,911       27,394       66,940  
Proceeds from insurance claim   –       –       (25,900 )     –  
Operating loss   (55,663 )     (251,678 )     (203,481 )     (461,603 )
Interest and other financing expense, net   11,882       12,841       56,957       51,253  
Other (income) expense, net   (1,523 )     (1,559 )     46,342       875  
Loss before income taxes and equity in net loss of equity-method investees   (66,022 )     (262,960 )     (306,780 )     (513,731 )
(Benefit) provision for income taxes   (4,097 )     9,551       (2,208 )     15,297  
Equity in net loss of equity-method investees   24       104       351       1,813  
Net loss $ (61,949 )   $ (272,615 )   $ (304,923 )   $ (530,841 )
               
Net loss per common share:              
Basic $ (0.68 )   $ (3.06 )   $ (3.36 )   $ (5.89 )
Diluted $ (0.68 )   $ (3.06 )   $ (3.36 )   $ (5.89 )
               
Shares used in the calculation of net loss per common share:              
Basic   90,996       89,024       90,736       90,127  
Diluted   90,996       89,024       90,736       90,127  
               

THE HAIN CELESTIAL GROUP, INC. AND SUBSIDIARIES
Consolidated Balance Sheets
(unaudited and in thousands)
       
  June 30, 2026   June 30, 2025
ASSETS      
Current assets:      
Cash and cash equivalents $ 58,078     $ 54,355  
Accounts receivable, net   121,022       154,440  
Inventories   149,275       248,731  
Prepaid expenses and other current assets   82,017       43,169  
Assets held for sale   5,882       29,603  
Total current assets   416,274       530,298  
Property, plant and equipment, net   184,665       264,730  
Goodwill   246,079       500,961  
Trademarks and other intangible assets, net   173,520       210,905  
Operating lease right-of-use assets, net   49,057       71,171  
Other assets   20,788       25,213  
Total assets $ 1,090,383     $ 1,603,278  
LIABILITIES AND STOCKHOLDERS’ EQUITY      
Current liabilities:      
Accounts payable $ 125,497     $ 188,307  
Accrued expenses and other current liabilities   143,560       68,426  
Current portion of long-term debt   557,552       7,653  
Liabilities related to assets held for sale   4,153       12,987  
Total current liabilities   830,762       277,373  
Long-term debt, less current portion   292       697,168  
Deferred income taxes   32,930       40,332  
Operating lease liabilities, noncurrent portion   44,409       65,284  
Other noncurrent liabilities   27,195       48,116  
Total liabilities   935,588       1,128,273  
Stockholders’ equity:      
Common stock   1,135       1,125  
Additional paid-in capital   1,243,863       1,238,402  
Retained (deficit) earnings   (258,245 )     46,678  
Accumulated other comprehensive loss   (101,463 )     (81,053 )
    885,290       1,205,152  
Less: Treasury stock   (730,495 )     (730,147 )
Total stockholders’ equity   154,795       475,005  
Total liabilities and stockholders’ equity $ 1,090,383     $ 1,603,278  
       

THE HAIN CELESTIAL GROUP, INC. AND SUBSIDIARIES
Consolidated Statements of Cash Flows
(unaudited and in thousands)
               
  Fourth Quarter   Fourth Quarter Year to Date
  2026   2025   2026   2025
CASH FLOWS FROM OPERATING ACTIVITIES              
Net loss $ (61,949 )   $ (272,615 )   $ (304,923 )   $ (530,841 )
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:              
Depreciation and amortization   13,508       11,357       52,552       44,259  
Deferred income taxes   (5,759 )     (1,798 )     (8,446 )     (4,423 )
Equity in net loss of equity-method investees   24       104       351       1,813  
Stock-based compensation, net   1,279       (1,273 )     5,471       8,149  
Goodwill impairment   42,293       227,364       193,219       428,882  
Long-lived asset and intangibles impairment   430       24,911       27,394       66,940  
Loss (gain) on sale of assets   209       (5,396 )     48,710       (3,194 )
Other non-cash items, net   718       1,365       3,589       2,138  
Increase (decrease) in cash attributable to changes in operating assets and liabilities:              
Accounts receivable   18,165       26,565       35,806       25,204  
Inventories   13,378       7,251       72,934       (3,354 )
Other current assets   2,148       11,393       (37,621 )     3,114  
Other assets and liabilities   (129 )     1,881       (4,138 )     1,320  
Accounts payable and accrued expenses   (12,872 )     (33,757 )     (6,629 )     (17,892 )
Net cash provided by (used in) operating activities   11,443       (2,648 )     78,269       22,115  
CASH FLOWS FROM INVESTING ACTIVITIES              
Purchases of property, plant and equipment   (4,609 )     (6,224 )     (20,613 )     (25,284 )
Proceeds from sale of assets, net   (204 )     197       102,566       13,970  
Investments and joint ventures, including proceeds from dispositions   –       10,000       –       12,570  
Proceeds from termination of net investment hedges   –       –       –       2,363  
Net cash (used in) provided by investing activities   (4,813 )     3,973       81,953       3,619  
CASH FLOWS FROM FINANCING ACTIVITIES              
Borrowings under bank revolving credit facility   34,000       65,000       190,000       221,000  
Repayments under bank revolving credit facility   (24,000 )     (59,500 )     (229,500 )     (245,500 )
Repayments under term loan   (1,875 )     (9,375 )     (108,600 )     (15,000 )
Payments of other debt, net   (24 )     (3,503 )     (2,666 )     (3,524 )
Employee shares withheld for taxes   (5 )     (33 )     (348 )     (1,414 )
Proceeds from termination of fair value hedge   –       –       –       552  
Net cash provided by (used in) financing activities   8,096       (7,411 )     (151,114 )     (43,886 )
Effect of exchange rate changes on cash   (959 )     16,016       (5,385 )     18,200  
Net increase in cash and cash equivalents   13,767       9,930       3,723       48  
Cash and cash equivalents at beginning of period   44,311       44,425       54,355       54,307  
Cash and cash equivalents at end of period $ 58,078     $ 54,355     $ 58,078     $ 54,355  
               

THE HAIN CELESTIAL GROUP, INC. AND SUBSIDIARIES
Net Sales, Gross Profit and Adjusted EBITDA by Segment
(unaudited and in thousands)
               
  North America   International   Corporate/Other   Hain Consolidated
Net Sales              
Net sales – Q4 FY26 $ 111,817     $ 151,252     $ –     $ 263,069  
Net sales – Q4 FY25 $ 205,790     $ 157,558     $ –     $ 363,348  
% change – FY26 net sales vs. FY25 net sales   (45.7 )%     (4.0 )%         (27.6 )%
               
Gross Profit              
Q4 FY26              
Gross profit $ 34,161     $ 25,042     $ –     $ 59,203  
Non-GAAP adjustments(1)   580       –       –       580  
Adjusted gross profit $ 34,741     $ 25,042     $ –     $ 59,783  
% change – FY26 gross profit vs. FY25 gross profit   (13.6 )%     (28.1 )%         (20.4 )%
% change – FY26 adjusted gross profit vs. FY25 adjusted gross profit   (12.1 )%     (28.1 )%         (19.6 )%
Gross margin   30.6 %     16.6 %         22.5 %
Adjusted gross margin   31.1 %     16.6 %         22.7 %
               
Q4 FY25              
Gross profit $ 39,522     $ 34,824     $ –     $ 74,346  
Non-GAAP adjustments(1)   (15 )     –       –       (15 )
Adjusted gross profit $ 39,507     $ 34,824     $ –     $ 74,331  
Gross margin   19.2 %     22.1 %         20.5 %
Adjusted gross margin   19.2 %     22.1 %         20.5 %
               
Adjusted EBITDA              
Q4 FY26              
Adjusted EBITDA $ 16,145     $ 12,324     $ (9,727 )   $ 18,742  
% change – FY26 Adjusted EBITDA vs. FY25 Adjusted EBITDA   55.3 %     (41.1 )%     14.9 %     (5.8 )%
Adjusted EBITDA margin   14.4 %     8.1 %         7.1 %
               
Q4 FY25              
Adjusted EBITDA $ 10,398     $ 20,938     $ (11,430 )   $ 19,906  
Adjusted EBITDA margin   5.1 %     13.3 %         5.5 %
               
(1)See accompanying table “Adjusted Gross Profit, Adjusted Operating Income, Adjusted Net (Loss) Income and Adjusted Net (Loss) Income per Diluted Share”
THE HAIN CELESTIAL GROUP, INC. AND SUBSIDIARIES
Net Sales, Gross Profit and Adjusted EBITDA by Segment
(unaudited and in thousands)
               
  North America   International   Corporate/Other   Hain Consolidated
Net Sales              
Net sales – Q4 FY26 YTD $ 685,053     $ 668,376     $ –     $ 1,353,429  
Net sales – Q4 FY25 YTD $ 888,626     $ 671,154     $ –     $ 1,559,780  
% change – FY26 net sales vs. FY25 net sales   (22.9 )%     (0.4 )%         (13.2 )%
               
Gross Profit              
Q4 FY26 YTD              
Gross profit $ 156,895     $ 115,217     $ –     $ 272,112  
Non-GAAP adjustments(1)   5,382       –       –       5,382  
Adjusted gross profit $ 162,277     $ 115,217     $ –     $ 277,494  
% change – FY26 gross profit vs. FY25 gross profit   (18.7 )%     (18.4 )%         (18.5 )%
% change – FY26 adjusted gross profit vs. FY25 adjusted gross profit   (16.6 )%     (18.4 )%         (17.4 )%
Gross margin   22.9 %     17.2 %         20.1 %
Adjusted gross margin   23.7 %     17.2 %         20.5 %
               
Q4 FY25 YTD              
Gross profit $ 192,910     $ 141,148     $ –     $ 334,058  
Non-GAAP adjustments(1)   1,764       –       –       1,764  
Adjusted gross profit $ 194,674     $ 141,148     $ –     $ 335,822  
Gross margin   21.7 %     21.0 %         21.4 %
Adjusted gross margin   21.9 %     21.0 %         21.5 %
               
Adjusted EBITDA              
Q4 FY26 YTD              
Adjusted EBITDA $ 61,236     $ 63,458     $ (35,686 )   $ 89,008  
% change – FY26 Adjusted EBITDA vs. FY25 Adjusted EBITDA   (6.5 )%     (26.2 )%     5.3 %     (21.8 )%
Adjusted EBITDA margin   8.9 %     9.5 %         6.6 %
               
Q4 FY25 YTD              
Adjusted EBITDA $ 65,470     $ 86,000     $ (37,681 )   $ 113,789  
Adjusted EBITDA margin   7.4 %     12.8 %         7.3 %
               
(1)See accompanying table “Adjusted Gross Profit, Adjusted Operating Income, Adjusted Net (Loss) Income and Adjusted Net (Loss) Income per Diluted Share”
               

THE HAIN CELESTIAL GROUP, INC. AND SUBSIDIARIES
Adjusted Gross Profit, Adjusted Operating Income, Adjusted Net (Loss) Income and Adjusted Net (Loss) Income per Diluted Share
(unaudited and in thousands, except per share amounts)
               
Reconciliation of Gross Profit, GAAP to Gross Profit, as Adjusted:              
  Fourth Quarter   Fourth Quarter Year to Date
  2026   2025   2026   2025
Gross profit, GAAP $ 59,203     $ 74,346     $ 272,112     $ 334,058  
Adjustments to Cost of sales:              
Plant closure related costs, net   580       (15 )     5,382       1,380  
Warehouse/manufacturing consolidation and other costs, net   –       –       –       384  
Gross profit, as adjusted $ 59,783     $ 74,331     $ 277,494     $ 335,822  
               
Reconciliation of Operating Loss, GAAP to Operating Income, as Adjusted:            
  Fourth Quarter   Fourth Quarter Year to Date
  2026   2025   2026   2025
Operating loss, GAAP $ (55,663 )   $ (251,678 )   $ (203,481 )   $ (461,603 )
Adjustments to Cost of sales:              
Plant closure related costs, net   580       (15 )     5,382       1,380  
Warehouse/manufacturing consolidation and other costs, net   –       –       –       384  
               
Adjustments to Operating expenses(a):              
Goodwill impairment   42,293       227,364       193,219       428,882  
Transaction and integration costs, net   9,390       86       14,125       (488 )
Productivity and transformation costs   4,520       5,033       22,039       21,530  
Certain litigation expenses, net(b)   1,703       1,219       4,867       3,473  
Long-lived asset and intangibles impairment   430       24,911       27,394       66,940  
Plant closure related costs, net   93       1       374       (165 )
Proceeds from insurance claim(c)   –       –       (25,900 )     –  
CEO succession   –       4,774       –       4,774  
Operating income, as adjusted $ 3,346     $ 11,695     $ 38,019     $ 65,107  
               
Reconciliation of Net Loss, GAAP to Net (Loss) Income, as Adjusted:              
  Fourth Quarter   Fourth Quarter Year to Date
  2026   2025   2026   2025
Net loss, GAAP $ (61,949 )   $ (272,615 )   $ (304,923 )     (530,841 )
Adjustments to Cost of sales:              
Plant closure related costs, net   580       (15 )     5,382       1,380  
Warehouse/manufacturing consolidation and other costs, net   –       –       –       384  
               
Adjustments to Operating expenses(a):              
Goodwill impairment   42,293       227,364       193,219       428,882  
Transaction and integration costs, net   9,390       86       14,125       (488 )
Productivity and transformation costs   4,520       5,033       22,039       21,530  
Certain litigation expenses, net(b)   1,703       1,219       4,867       3,473  
Long-lived asset and intangibles impairment   430       24,911       27,394       66,940  
Plant closure related costs, net   93       1       374       (165 )
Proceeds from insurance claim(c)   –       –       (25,900 )     –  
CEO succession   –       4,774       –       4,774  
               
Adjustments to Interest and other expense (income), net(d):              
Unrealized currency losses   328       3,116       951       3,941  
Loss (gain) on sale of assets   209       (5,396 )     48,710       (3,194 )
               
Adjustments to (Benefit) provision for income taxes:              
Net tax impact of non-GAAP adjustments   (1,992 )     9,838       (1,859 )     11,453  
Net (loss) income, as adjusted $ (4,395 )   $ (1,684 )   $ (15,621 )     8,069  
Net loss margin   (23.5 )%     (75.0 )%     (22.5 )%     (34.0 )%
Adjusted net (loss) income margin   (1.7 )%     (0.5 )%     (1.2 )%     0.5 %
               
Diluted shares used in the calculation of net loss per common share:   90,996       89,024       90,736       90,127  
Diluted shares used in the calculation of adjusted net (loss) income per common share:   90,996       89,024       90,736       90,380  
               
Diluted net loss per common share, GAAP $ (0.68 )   $ (3.06 )   $ (3.36 )   $ (5.89 )
Diluted net (loss) income per common share, as adjusted $ (0.05 )   $ (0.02 )   $ (0.17 )   $ 0.09  
               
(a) Operating expenses include amortization of acquired intangibles, selling, general and administrative expenses, productivity and transformation costs, long-lived asset and intangibles impairment and goodwill impairment.
(b) Expenses and items relating to securities class action, baby food litigation and SEC investigation.
(c) Represents a receivable under the Company’s representation and warranty insurance related to one of its prior acquisitions, which was collected on January 2, 2026.
(d) Interest and other expense (income), net includes interest and other financing expenses, net, unrealized currency losses, loss (gain) on sale of assets and other expense, net.
               
THE HAIN CELESTIAL GROUP, INC. AND SUBSIDIARIES
Organic Net Sales Growth by Segment
(unaudited and in thousands)
           
Q4 FY26 North America   International   Hain Consolidated
Net sales $ 111,817     $ 151,252     $ 263,069  
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories   14,056       731       14,787  
Less: Impact of foreign currency exchange   (18 )     1,596       1,578  
Organic net sales $ 97,779     $ 148,925     $ 246,704  
           
Q4 FY25          
Net sales $ 205,790     $ 157,558     $ 363,348  
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories   109,615       2,475       112,090  
Organic net sales $ 96,175     $ 155,083     $ 251,258  
           
Net sales decline   (45.7 )%     (4.0 )%     (27.6 )%
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories   (47.4 )%     (1.0 )%     (26.2 )%
Less: Impact of foreign currency exchange   (0.0 )%     1.0 %     0.4 %
Organic net sales growth (decline)   1.7 %     (4.0 )%     (1.8 )%
           
Q4 FY26 YTD North America   International   Hain Consolidated
Net sales $ 685,053     $ 668,376     $ 1,353,429  
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories   252,165       5,659       257,824  
Less: Impact of foreign currency exchange   249       29,363       29,612  
Organic net sales $ 432,639     $ 633,354     $ 1,065,993  
           
Q4 FY25 YTD          
Net sales $ 888,626     $ 671,154     $ 1,559,780  
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories   456,786       9,251       466,037  
Organic net sales $ 431,840     $ 661,903     $ 1,093,743  
           
Net sales decline   (22.9 )%     (0.4 )%     (13.2 )%
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories   (23.1 )%     (0.5 )%     (12.6 )%
Less: Impact of foreign currency exchange   0.0 %     4.4 %     1.9 %
Organic net sales growth (decline)   0.2 %     (4.3 )%     (2.5 )%
           

THE HAIN CELESTIAL GROUP, INC. AND SUBSIDIARIES
Organic Net Sales Growth by Category
(unaudited and in thousands)
                       
Q4 FY26 Baby & Kids   Beverages   Meal Prep   Snacks   Personal Care Hain Consolidated
Net sales $ 52,313     $ 55,370     $ 135,004     $ 8,515     $ 11,867     $ 263,069  
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories   167       –       1,444       1,309       11,867       14,787  
Less: Impact of foreign currency exchange   203       778       569       28       –       1,578  
Organic net sales $ 51,943     $ 54,592     $ 132,991     $ 7,178     $ –     $ 246,704  
                       
Q4 FY25                      
Net sales $ 59,327     $ 55,783     $ 140,196     $ 93,324     $ 14,718     $ 363,348  
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories   879       42       10,852       85,599       14,718       112,090  
Organic net sales $ 58,448     $ 55,741     $ 129,344     $ 7,725     $ –     $ 251,258  
                       
Net sales decline   (11.8 )%     (0.7 )%     (3.7 )%     (90.9 )%     (19.4 )%     (27.6 )%
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories   (1.0 )%     0.0 %     (6.9 )%     (83.8 )%   n/a       (26.2 )%
Less: Impact of foreign currency exchange   0.3 %     1.4 %     0.4 %     0.0 %   n/a       0.4 %
Organic net sales (decline) growth   (11.1 )%     (2.1 )%     2.8 %     (7.1 )%   n/a       (1.8 )%
                       
Q4 FY26 YTD Baby & Kids   Beverages   Meal Prep   Snacks   Personal Care Hain Consolidated
Net sales $ 214,828     $ 255,979     $ 620,121     $ 213,208     $ 49,293     $ 1,353,429  
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories   2,849       32       20,732       184,918       49,293       257,824  
Less: Impact of foreign currency exchange   3,667       8,897       16,013       1,035       –       29,612  
Organic net sales $ 208,312     $ 247,050     $ 583,376     $ 27,255     $ –     $ 1,065,993  
                       
Q4 FY25 YTD                      
Net sales $ 241,552     $ 245,147     $ 639,507     $ 371,012     $ 62,562     $ 1,559,780  
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories   5,291       145       56,252       341,787       62,562       466,037  
Organic net sales $ 236,261     $ 245,002     $ 583,255     $ 29,225     $ –     $ 1,093,743  
                       
Net sales (decline) growth   (11.1 )%     4.4 %     (3.0 )%     (42.5 )%     (21.2 )%     (13.2 )%
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories   (0.8 )%     (0.0 )%     (5.5 )%     (36.1 )%   n/a       (12.6 )%
Less: Impact of foreign currency exchange   1.5 %     3.6 %     2.5 %     0.3 %   n/a       1.9 %
Organic net sales (decline) growth   (11.8 )%     0.8 %     0.0 %     (6.7 )%   n/a       (2.5 )%

THE HAIN CELESTIAL GROUP, INC. AND SUBSIDIARIES
Adjusted EBITDA
(unaudited and in thousands)
               
  Fourth Quarter   Fourth Quarter Year to Date
  2026   2025   2026   2025
               
Net loss $ (61,949 )   $ (272,615 )   $ (304,923 )   $ (530,841 )
               
Depreciation and amortization   13,508       11,357       52,552       44,259  
Equity in net loss of equity-method investees   24       104       351       1,813  
Interest expense, net   10,431       11,689       50,154       47,773  
(Benefit) provision for income taxes   (4,097 )     9,551       (2,208 )     15,297  
Stock-based compensation, net   1,279       (1,273 )     5,471       8,149  
Unrealized currency losses   328       3,116       951       3,823  
Certain litigation expenses, net(a)   1,703       1,219       4,867       3,473  
Proceeds from insurance claim(b)   –       –       (25,900 )     –  
Restructuring activities              
Productivity and transformation costs   4,520       5,033       22,039       21,530  
Plant closure related costs, net   673       (14 )     2,206       1,215  
Warehouse/manufacturing consolidation and other costs, net   –       –       –       384  
CEO succession   –       4,774       –       4,774  
Acquisitions, divestitures and other              
Transaction and integration costs, net   9,390       86       14,125       (488 )
Loss (gain) on sale of assets   209       (5,396 )     48,710       (3,194 )
Impairment charges              
Goodwill impairment   42,293       227,364       193,219       428,882  
Long-lived asset and intangibles impairment   430       24,911       27,394       66,940  
Adjusted EBITDA $ 18,742     $ 19,906     $ 89,008     $ 113,789  
               
(a) Expenses and items relating to securities class action, baby food litigation and SEC investigation.
(b) Represents a receivable under the Company’s representation and warranty insurance related to one of its prior acquisitions, which was collected on January 2, 2026.
               
THE HAIN CELESTIAL GROUP, INC. AND SUBSIDIARIES
Free Cash Flow
(unaudited and in thousands)
               
  Fourth Quarter   Fourth Quarter Year to Date
  2026   2025   2026   2025
               
Net cash provided by (used in) operating activities $ 11,443     $ (2,648 )   $ 78,269     $ 22,115  
Purchases of property, plant and equipment   (4,609 )     (6,224 )     (20,613 )     (25,284 )
Free cash flow $ 6,834     $ (8,872 )   $ 57,656     $ (3,169 )
               
THE HAIN CELESTIAL GROUP, INC. AND SUBSIDIARIES
Net Debt
(unaudited and in thousands)
       
  June 30, 2026   June 30, 2025
Debt      
Current portion of long-term debt $ 557,552   $ 7,653
Long-term debt, less current portion   292     697,168
Total debt   557,844     704,821
Less: Cash and cash equivalents   58,078     54,355
Net debt $ 499,766   $ 650,466
       

NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) — Brookfield Corporation (NYSE: BN, TSX: BN) and Brookfield Asset Management (NYSE: BAM, TSX: BAM) today announced that they will host their Investor Day in New York on Thursday, September 17, 2026.

Brookfield Asset Management’s event will run from 12:45 to 2:45 p.m. (ET), followed by Brookfield Corporation’s from 3:00 to 5:00 p.m. (ET).

The live webcast, along with copies of the presentations, can be accessed at www.brookfield.com/investorday or through www.bn.brookfield.com and www.bam.brookfield.com.

Please register for the webcast at least 15 minutes before the event to ensure an optimal viewing experience. For those unable to view the event live, a replay will be available on each company’s website shortly after the event.

About Brookfield

Brookfield is a leading global investment firm with more than $1 trillion in assets under management. The firm owns and operates high-quality businesses and real assets that provide essential services and form the backbone of the global economy. Brookfield invests on behalf of institutions and individuals around the world across infrastructure, energy, private equity, real estate, and credit. With more than a century of operating experience and a global presence in over 50 countries, Brookfield deploys long-term capital to generate sustainable value for its clients and shareholders.

For more information about Brookfield Corporation, please visit our investor relations website at www.bn.brookfield.com or contact:

Media:
Kerrie McHugh
Tel: (212) 618-3469
Email: kerrie.mchugh@brookfield.com

Investor Relations:
Katie Battaglia
Tel: (416) 359-8544
Email: katie.battaglia@brookfield.com

For more information about Brookfield Asset Management, please visit our investor relations website at www.bam.brookfield.com or contact:

Media:
Simon Maine
Tel: (332) 298-0447
Email: simon.maine@brookfield.com
Investor Relations:
Jason Fooks
Tel: (212) 417-2442
Email: jason.fooks@brookfield.com

Sale would simplify Hain’s portfolio and create a focused North American business; Net proceeds from the transaction would be used to reduce debt

Hain Celestial Enters Into Definitive Agreement to Sell International Business

Sale would simplify Hain’s portfolio and create a focused North American business; Net proceeds from the transaction would be used to reduce debt
Sale would simplify Hain’s portfolio and create a focused North American business; Net proceeds from the transaction would be used to reduce debt

HOBOKEN, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) — As part of its ongoing strategic review, Hain Celestial announced today it has reached a definitive agreement to sell its International business to global private equity firm AURELIUS for an estimated $323 million in cash. Net proceeds from the transaction are expected to range between $305 million and $310 million. Upon closing of the transaction, the proceeds would be used to reduce the Company’s debt. The agreement reflects the Board of Directors’ continued work to advance the Company’s strategic review, evaluate available alternatives and pursue paths designed to maximize value for all stakeholders.

The sale will include the majority of Hain’s International business operations and is inclusive of brands such as Ella’s Kitchen® baby and kids foods, Joya® and Natumi® plant-based beverages, Hartley’s® jelly, as well as Linda McCartney® Foods, Cully & Sully®, Yorkshire Provender®, and New Covent Garden® soups, among others.

Alison Lewis, Hain Celestial’s President and CEO, said, “Completing the transaction announced today would advance our strategy to simplify our portfolio and enable us to focus our resources on further reducing the Company’s debt. The resulting North American business would feature leading brands in attractive categories with a more streamlined operating model and greater focus on core growth opportunities.”

The Company’s resulting portfolio of brands in North America will include Celestial Seasonings® teas, The Greek Gods® yogurt and Earth’s Best® Organic across its flagship categories of tea, yogurt and baby & kids foods. The portfolio also includes Spectrum® Organic cooking oils, MaraNatha® nut butters and Imagine® broths.

Lewis continued, “I want to recognize the incredible people behind our International brands and business. Their dedication, expertise and commitment over many years is greatly appreciated. They have built remarkable brands, which we are confident will thrive under the new ownership.”

Hain Celestial remains in discussions with its lenders regarding an amendment to its credit agreement to extend the maturity date beyond December 22, 2026. The transaction with AURELIUS is conditioned upon the Company securing this amendment and may be terminated by AURELIUS if the amendment is not obtained within 30 days of signing. While there can be no assurance that an amendment will be obtained, the Board believes that extending the maturity date and completing the transaction would be in the best interests of the Company and its stakeholders.

The Company continues to focus on simplifying the organization and executing a plan to align its cost structure with the scale of the future North American business. Hain has developed detailed cost reduction plans and is moving with urgency to deliver these actions. The Company expects to implement cost reduction actions generating approximately $16 million of annualized savings on a run rate basis as compared to fiscal 2026. The Board and management team remain focused on swiftly executing these actions, while continuing to evaluate and advance all available paths under the strategic review to maximize value for the benefit of all stakeholders.

The agreement with AURELIUS has been unanimously approved by the Company’s Board. The transaction is subject to closing conditions, including regulatory approvals and an amendment to the Company’s credit agreement as described above. Subject to satisfaction of those conditions, the transaction is expected to close in Hain Celestial’s fiscal second quarter ending December 31, 2026.

Goldman Sachs is serving as the Company’s financial advisor on the transaction, and DLA Piper’s London team is serving as legal counsel.

The Company will discuss the proposed transaction during its Q4 2026 earnings conference call later today.

About The Hain Celestial Group
Hain Celestial is a leading global health and wellness company whose purpose is to inspire healthier living for people, communities and the planet through better-for-you brands. For more than 30 years, Hain Celestial has intentionally focused on delivering nutrition and well-being that positively impacts today and tomorrow. Headquartered in Hoboken, N.J., Hain Celestial’s products across beverages, yogurt, baby/kids and meal preparation are marketed and sold around the world. Our leading brands include Celestial Seasonings® teas, The Greek Gods® yogurt, Earth’s Best® Organic and Ella’s Kitchen® baby and kids foods, Joya® and Natumi® plant-based beverages, Hartley’s® jelly, as well as Cully & Sully®, Yorkshire Provender®, New Covent Garden® soups, among others. For more information, visit www.hain.com and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward-looking statements. The words “believe,” “expect,” “anticipate,” “may,” “should,” “plan,” “intend,” “potential,” “will” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, among other things, our beliefs or expectations relating to our future performance, results of operations and financial condition, including statements about the Company’s plan to sell its International business; the expected timetable for completing the transaction; cost-cutting initiatives; the outcome of the Company’s discussions with its lenders; the Company’s ability to create stakeholder value; and the outcome of the Company’s strategic review.

Risks and uncertainties that may cause actual results to differ materially from forward-looking statements include our ability to satisfy the conditions to the closing of the contemplated transaction, which may include conditions outside of our control; the upcoming maturity of the credit agreement in December 2026 and our ability to secure an extension of the maturity date with our lenders, including that any such amendment requires the consent of all lenders and that the failure to obtain it within the required period would permit the purchaser to terminate the agreement; and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, our Annual Report on Form 10-K expected to be filed today and our other filings from time to time with the U.S. Securities and Exchange Commission.

We undertake no obligation to update forward-looking statements to reflect actual results or changes in assumptions or circumstances, except as required by applicable law.

Media Contact:
Justin Godley
Justin.Godley@hain.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/585b1980-35bb-4dc4-aac1-be9029044b19

  • Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer).
  • Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatment-related change in adults and pediatric patients.
  • FET-PET imaging is recommended in international clinical practice guidelines, including NCCN Guidelines®.
  • Pixclara expands Telix’s industry-leading Precision Medicine business and reinforces the Company’s leadership in diagnostics and targeted radiopharmaceutical therapies (together, “theranostics”).

MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or 18F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer).

Pixclara is a radioactive diagnostic drug indicated for use with positron emission tomography (PET) to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older.

PET imaging with floretyrosine F 18 (FET-PET) is recommended in international clinical practice guidelines for the imaging of gliomas, including NCCN Guidelines®1, but until now there has not been an FDA-approved product available in the U.S.

Gliomas are the most common form of central nervous system (CNS) cancer, accounting for approximately 30% of all brain and CNS tumors and 80% of all malignant brain tumors2. In the U.S., approximately 24,000 new glioma cases are diagnosed each year3, representing a significant unmet addressable need.

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, said, “FDA approval of Pixclara will enable broad access in the U.S. to FET-PET imaging, which is already recognized in international clinical practice guidelines. As the first FDA-approved PET imaging drug for glioma, Pixclara will provide physicians in the U.S. with more certainty in their diagnoses and greater confidence in their treatment planning for patients.”

Kelly Sitkin, President and CEO, American Brain Tumor Association, said, “The approval of Pixclara will advance glioma care by enabling more precise monitoring, complementing the role of MRI. We welcome the FDA’s decision, which provides a pathway to access this technology in the U.S. and helps address a critical unmet need in brain cancer diagnostics.”

Patrick Wen, MD, E. Antonio Chiocca, MD, PhD, Family Endowed Chair in Neuro-Oncology at Mass General Brigham Cancer Institute, said, “Having an FDA-approved FET-PET product with high diagnostic accuracy will make a significant, positive difference to the management of patients with gliomas. This is a very positive step forward for brain cancer imaging and treatment planning.”

About Pixclara (floretyrosine F 18)

Pixclara® is an intravenous positron emission tomography (PET) imaging drug for the differentiation of recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older. It comprises a small molecule targeting compound labeled with a diagnostic radioisotope, fluorine-18. After administration into the bloodstream, Pixclara targets membrane transport proteins known as L-type amino acid transporters 1 and 2 (LAT1 and LAT2). Once bound, energy emissions from the radioisotope can be detected by a PET scanner. Pixclara (TLX101-Px) is also the subject of a Phase 3 registrational study for potential indication expansion for the diagnosis of brain metastases4.

Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer).

INDICATIONS AND USAGE 
PIXCLARA is indicated for use with positron emission tomography (PET) to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS
Risk for Misinterpretation
Image misinterpretation may occur with PIXCLARA PET. A negative image does not rule out the presence of recurrent or progressive glioma and a positive image does not confirm the presence of recurrent or progressive glioma. Equivocal findings may occur with PIXCLARA PET, including low-level or atypical uptake patterns, which may result in false positive or false negative interpretations.

Interpret PIXCLARA PET findings with caution and correlate results with available clinical evaluations, such as histopathology, cross-sectional imaging, and/or clinical history to support appropriate clinical decision-making.

Radiation Risks
PIXCLARA contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe drug handling to protect patients and health care providers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration.

ADVERSE REACTIONS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of PIXCLARA was evaluated in 382 patients with gliomas. Among these 382 patients, 371 adult patients received at least one intravenous dose of PIXCLARA at a mean activity of 204 ± 18 MBq (5.5 ± 0.47 mCi). The remaining 11 pediatric patients received at least one intravenous dose of PIXCLARA at a mean activity of 155 ± 53.5 MBq (4.2 ± 1.4 mCi).

The mean age of the patients was 57 years (range: 5 years to 86 years). Sex was 59% male, 37% female, and 3% unreported. Distribution by race was 26% White, 6% Asian, <1% Black or African American, and 67% other or unreported. Distribution by ethnicity was 3% Hispanic/Latino, 96% non-Hispanic/Latino, and <1% unknown or unreported.

Adverse reactions that occurred in ≥0.5% of patients receiving PIXCLARA were headache (0.5%).

Adverse reactions that occurred in <0.5% of patients were nausea, injection site reaction, fatigue, and malaise.

Adverse Reactions in Pediatric Patients

Overall, the safety profile observed in pediatric patients from the clinical study was consistent with the safety profile in adult patients.

Please note that this information is not comprehensive.
Please see the Full Prescribing Information at https://telixpharma.com/pixclara-uspi

You are encouraged to report suspected adverse reactions of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report adverse reactions to Telix Pharmaceuticals (US) by calling 1-844-455-8638 or emailing pharmacovigilance@telixpharma.com.

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease.

Telix’s commercial franchise is anchored by its precision diagnostics portfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S., and Gozellix® (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. Food and Drug Administration (FDA) for prostate imaging, and Pixclara® (floretyrosine F18) approved by the FDA for glioma imaging. The Company’s late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (131I-iodofalan) in recurrent glioblastoma, and TLX250-Tx (lutetium (177Lu) girentuximab tetraxetan) in kidney cancer, additionally complemented by a deep pipeline of next generation candidates. TLX591-Tx, TLX101-Tx and TLX250-Tx have not received marketing authorizations in any jurisdiction.

Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook.

Investor Relations

Annie Kasparian
annie.kasparian@telixpharma.com

Charlene Jaw
charlene.jaw@telixpharma.com

Media

Eliza Schleifstein
917.763.8106 (Mobile)
eliza@schleifsteinpr.com

 
     

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

___________________
1 Galldiks et al. Lancet Oncol. 2025 (Joint guidelines from the European Association of Nuclear Medicine (EANM), European Association of Neuro-Oncology (EANO), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Response Assessment in Neuro-Oncology (RANO), The European Society for Pediatric Oncology and The Response Assessment in Pediatric Neuro-Oncology for the characterization of recurrence in glioma patients); National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers V3.2026.
2 Goodenberger et al. Cancer Genet. 2012.
3 CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2018-2022. Neuro-Oncology. 2025.
4 Investigational New Drug (IND) application successfully cleared, with Study May Proceed notification received from FDA. Telix ASX disclosure August 20, 2026.

Key Takeaways:

  • Parsons secured nine “Awardable” designations across two leading Department of War digital marketplaces designed to rapidly deploy operational capabilities to warfighters at the edge.
  • Three solutions were recognized in Platform One and six in Tradewinds, expanding Parsons’ presence across the defense technology ecosystem.
  • The designations enable faster evaluation, procurement, and deployment of innovative mission-focused capabilities.

CHANTILLY, Va., Sept. 14, 2026 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) announced today that nine of its digital solutions have been designated as “Awardable” across leading Department of War (DoW) digital marketplaces, accelerating government access to proven, mission-ready technologies.

For decades, Parsons has delivered innovative, rapid solutions to national security challenges that face the United States and its allies.

“Having nine Parsons solutions designated as ‘Awardable’ demonstrates the depth and maturity of our mission-ready defense product portfolio and reinforces our ability to deliver innovative capabilities that address our customers’ most critical national security challenges,” said Aaron Wajsgras, vice president of product strategy & commercialization for Parsons. “This achievement validates the mission impact of our products while meeting the Department of War’s mission requirements of faster and easier acquisition and deployment in support of critical national security priorities.”

Tradewinds Solutions Marketplace

Six Parsons solutions are designated “Awardable” in the Tradewinds Solutions Marketplace, a Department of War marketplace designed to accelerate the procurement and adoption of innovative commercial technologies through streamlined acquisition pathways. Parsons’ awardable solutions on Tradewinds include Ground Operations Command as a Service (GOCaaS), OrbitXchange™, SPARTAN Antenna, DroneArmor™, C2Core® Air, and Assured Positioning System (APS™).

  • GOCaaS is a cloud-native satellite operations platform that provides automated commanding, telemetry analysis, orbit determination, maneuver planning, mission data delivery, and constellation management for any satellite, in any orbit, and any constellation size.
  • OrbitXchange™ is an automated, cloud-native, cybersecure satellite communications solution that leverages commercial antenna networks to provide flexible, scalable, automated, and operationally proven ground station access.
  • SPARTAN Antenna is an advanced phased-array-fed parabolic antenna system that enables simultaneous satellite commanding, telemetry, and mission data collection for up to eight spacecraft simultaneously through electronically steerable beams.
  • DroneArmor™ is a fully automated counter-unmanned aircraft system (C-UAS) command-and-control platform that integrates sensors, effectors, and AI-enabled software to provide real-time drone threat detection, tracking, and response capabilities.
  • C2Core® Air is a cloud-native command and control solution that enables end-to-end air operations planning, tasking, execution monitoring, and combat assessment within a distributed operating environment. Using the Strategy through Assessment workflow developed for C2Core, C2Core Air provides seamless integration of strategic, operational, and tactical levels of planning and mission management.
  • APS™ provides resilient positioning, navigation, and timing (PNT) information when GPS or other global navigation satellite systems (GNSS) are jammed, spoofed, or otherwise unavailable or unreliable. APS uses proprietary satellite-based hybrid technology to produce reliable PNT data from non-GPS/non-GNSS RF transmissions from commercial and non-commercial communications satellites, including low-Earth orbit (LEO) vehicles. With APS, critical terrestrial and airborne applications that rely on PNT can continue to operate and execute their missions when GPS is undependable or unavailable.

The inclusion of these products in the Tradewinds Solutions Marketplace makes it easier for defense customers to rapidly identify, evaluate, and acquire trusted technologies that address evolving mission requirements.

Platform One Solutions Marketplace

Three Parsons solutions are designated “Awardable” in the Platform One Solutions Marketplace, one of DoW’s premier technology environments for discovering, evaluating, and rapidly acquiring vetted software capabilities. Sponsored by the U.S. Air Force, Platform One features post-competition solutions that enable organizations to identify and field mission-ready technologies. Parsons’ awardable solutions on Platform One include its Modern Extract, Transform, and Load (METAL) software application development approach, Support Velocity Helpdesk Automation solution, and TReX signal and channel emulation solution.

  • METAL is a modern application development approach designed to handle large and complex data workloads, integrate diverse data sources, and provide resilient, scalable architectures using containerization, microservices, and Kubernetes.
  • Support Velocity is an information technology service management (ITSM) solution that uses artificial intelligence (AI) and machine learning (ML) to categorize help desk tickets, reducing technician workload and improving resolution times.
  • TReX is a software- and commercial off-the-shelf hardware-based signal and channel emulation solution that enables realistic electronic warfare testing, evaluation, and warfighter training using representative signals of interest.

The availability of these products on the Platform One Solutions Marketplace enables defense customers to rapidly identify, evaluate, and acquire mission-ready software and technology solutions.

For more information about Parsons awardable solutions on the defense marketplace, visit: Awardable Defense Marketplace Solutions | Parsons Corporation

About Parsons:
Parsons (NYSE: PSN) is a leading disruptive technology provider in the national security and global infrastructure markets, with capabilities across cyber and electronic warfare, space and missile defense, transportation, water and environment, urban development, and critical infrastructure protection. Please visit Parsons.com and follow us on LinkedIn to learn how we’re making an impact.

Forward-Looking Statements:
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on our current expectations, beliefs and assumptions, and are not guarantees of future performance. Forward-looking statements are inherently subject to uncertainties, risks, changes in circumstances, trends and factors that are difficult to predict, many of which are outside of our control. Accordingly, actual performance, results and events may vary materially from those indicated in the forward-looking statements, and you should not rely on the forward-looking statements as predictions of future performance, results or events. Numerous factors could cause actual future performance, results and events to differ materially from those indicated in the forward-looking statements, including, among others: any issue that compromises our relationships with the U.S. federal government or its agencies or other state, local or foreign governments or agencies; any issues that damage our professional reputation; changes in governmental priorities that shift expenditures away from agencies or programs that we support; our dependence on long-term government contracts, which are subject to the government’s budgetary approval process; the size of our addressable markets and the amount of government spending on private contractors; failure by us or our employees to obtain and maintain necessary security clearances or certifications; failure to comply with numerous laws and regulations; changes in government procurement, contract or other practices or the adoption by governments of new laws, rules, regulations and programs in a manner adverse to us; the termination or nonrenewal of our government contracts, particularly our contracts with the U.S. federal government; our ability to compete effectively in the competitive bidding process and delays, contract terminations or cancellations caused by competitors’ protests of major contract awards received by us; our ability to generate revenue under certain of our contracts; any inability to attract, train or retain employees with the requisite skills, experience and security clearances; the loss of members of senior management or failure to develop new leaders; misconduct or other improper activities from our employees or subcontractors; our ability to realize the full value of our backlog and the timing of our receipt of revenue under contracts included in backlog; changes in the mix of our contracts and our ability to accurately estimate or otherwise recover expenses, time and resources for our contracts; changes in estimates used in recognizing revenue; internal system or service failures and security breaches; and inherent uncertainties and potential adverse developments in legal proceedings, including litigation, audits, reviews and investigations, which may result in materially adverse judgments, settlements or other unfavorable outcomes. These factors are not exhaustive and additional factors could adversely affect our business and financial performance. For a discussion of additional factors that could materially adversely affect our business and financial performance, see the factors included under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and our other filings with the Securities and Exchange Commission. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. We assume no obligation to update any forward-looking statement made in this press release that becomes untrue because of subsequent events, new information or otherwise, except to the extent we are required to do so by law.

Media Contact:                                        
Bernadette Miller
+1 980.253.9781
bernadette.miller@parsons.com

Investor Relations Contact:
Dave Spille
+1 703.775.6191
Dave.Spille@parsons.us

Enhanced rail-pressure control, improved durability and more adaptable architecture deliver greater performance and integration flexibility, strengthening the case for broader adoption by OEMs and operators worldwide

VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) — Westport Fuel Systems Inc. (“Westport”) (TSX:WPRT / Nasdaq: WPRT), today announced Cespira, its joint venture with Volvo Group, released new technical details of HPDI™ 3.0, the next generation of its proven High Pressure Direct Injection fuel system.

HPDI 3.0 retains proven HPDI combustion principles while advancing fuel rail-pressure control, hardware durability and system integration. The new fuel system supports liquefied natural gas (LNG) and renewable bio-based liquefied natural gas (bioLNG) today while preserving adaptability for future low- and zero-carbon fuels.

Performance Enhancements
At its core, HPDI 3.0 incorporates a new fuel rail-pressure control architecture that improves fuel economy and engine performance while simplifying OEM calibration. Higher injection pressure capability unlocks greater power and efficiency from the latest high-performance compression-ignition engines, while the architecture is designed to support compliance with future global emissions regulations.

Improved Durability and Greater Integration Flexibility
The new hardware integrates proven HPDI injector dynamic sealing technology to enhance component service life. A modular fuel rail-pressure control architecture gives OEMs greater packaging flexibility across different engine layouts. The new system supports larger engines, including V12 and other multi-bank configurations, by allowing fuel pressure control across separate cylinder banks. This broadens the potential application of HPDI 3.0 across demanding on-road and off-road sectors.

Built for Natural Gas and Biogas Today, Adaptable for Future Fuels
HPDI 3.0 reinforces the near-term value of natural gas and renewable natural gas for heavy-duty transport by enabling the use of LNG and bioLNG with diesel-like performance, improved efficiency and attractive total cost of ownership. The architecture also maintains a clear pathway for future fuel-specific applications, including hydrogen, as those markets develop.

“Cespira’s revenue increased 125% year over year from Q2 2025 to Q2 2026, underscoring strong market validation for HPDI technology. With continued gains in efficiency, attractive total cost of ownership and improved fuel price stability, we believe HPDI is well positioned to grow adoption momentum with OEMs and fleets,” said Dan Sceli, Chief Executive Officer of Westport.

“HPDI 3.0 strengthens both the immediate and long-term business case for OEMs. More precise fuel rail pressure control, higher injection pressure capability, enhanced durability and improved fuel economy make HPDI 3.0 a more compelling proposition for LNG and BioLNG applications. The architecture is also more readily adaptable to future fuel-specific systems for hydrogen and low-carbon fuels, giving OEMs greater flexibility to build on their HPDI investment and expand their product portfolios as those fuel markets develop,” said Scott Baker, CTO of Cespira.

HPDI 3.0 builds on a proven technology foundation, with the current generation accumulating more than 3 billion kilometers of real-world operation across 12,000+ trucks in over 35 countries. Cespira will begin production of HPDI 3.0 in the fourth quarter of 2026, with the first HPDI 3.0 equipped vehicles expected on the road in early 2027.

More information about Cespira can be found at www.Cespira.com.

About Westport

Westport is a technology and innovation company connecting synergistic technologies to power a cleaner tomorrow. As a leading supplier of affordable, alternative fuel, low-emissions transportation technologies, we design, manufacture, and supply advanced components and systems that enable the transition from traditional fuels to cleaner energy solutions.

Our proven technologies support a wide range of alternative fuels – including natural gas, renewable natural gas, and hydrogen – empowering OEMs and commercial transportation industries to meet performance demands, regulatory requirements, and climate targets in a cost-effective way. With decades of expertise and a commitment to engineering excellence, Westport is helping our partners achieve sustainability goals-without compromising performance or cost-efficiency – making clean, scalable transport solutions a reality.

Westport is headquartered in Vancouver, Canada.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding, among other things, the anticipated performance, efficiency and emissions characteristics of Cespira’s HPDI™3.0 fuel system; the timing for commencement of production for HPDI 3.0 equipped vehicles and for such vehicles to be in operation; and the intentions, plans and actions of our joint venture and other partners. Forward-looking statements are based on management’s current expectations and assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. These risks, uncertainties and assumptions include, among others: the ability of Westport, Cespira and their partners to successfully develop, integrate, validate, and certify HPDI technology on expected timelines or at all; the results of testing and development activities and the ability to achieve required performance, durability, reliability, safety and regulatory requirements; the receipt and timing of required regulatory approvals, certifications and homologation, changes in laws, regulations and standards and incentive programs applicable to emissions, engine certification and vehicle classification; competitive technologies and products; general economic and market conditions; as well as other risk factors, uncertainties and assumptions that may affect our actual results, performance, achievements or financial position discussed in our most recent Annual Information Form and other filings with securities regulators. Readers should not place undue reliance on any such forward-looking statements, which speak only as of the date they were made. We disclaim any obligation to publicly update or revise such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in these forward looking statements except as required by National Instrument 51-102. The contents of any website, RSS feed or twitter account referenced in this press release are not incorporated by reference herein.

Contact Information
Westport Investor Relations
T: +1 604-718-2046

TORONTO, Sept. 14, 2026 (GLOBE NEWSWIRE) — TRX Gold Corporation (TSX: TRX) (NYSE American: TRX) (the “Company” or “TRX Gold”) is pleased to report that the Company has been added to the MVIS® Global Junior Gold Miners Index (“MVGDXJ”) following the Q3 2026 index rebalance announcement on September 11, 2026.

Stephen Mullowney, TRX Gold CEO commented: “Following our addition to the S&P/TSX Global Mining Index announced on March 28, I am very pleased to announce that TRX Gold has now also met the criteria for inclusion in the MVGDXJ, which is designed to track the overall performance of small-capitalization companies that are involved primarily in the mining of gold and/or silver1. TRX Gold’s inclusion in this major index has the potential to maintain and attract additional global institutional investment into the Company and increase liquidity, with the MVGDXJ being an important benchmark requirement for many large investment funds. This addition also positions the Company for possible inclusion in related funds and ETFs, including the Van Eck Junior Gold Miners ETF (“GDXJ®”) which seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVGDXJ. Congratulations to the entire team on achieving this important milestone!”

For the MVIS Global Junior Gold Miners Index (MVGDXJ), the Q3 2026 rebalance schedule is as follows:

  • Index data / reference date: August 31, 2026
  • Rebalance announcement: September 11, 2026
  • Index Implementation / rebalance date: September 18, 2026
  • New composition becomes effective: September 21, 2026, the next trading day after implementation.

About MVGDXJ1
The MVIS® Global Junior Gold Miners Index (MVGDXJ) tracks the performance of the most liquid small-cap companies in the global gold and silver mining industries. This is a modified market cap-weighted index, and only includes companies that generate at least 50% of their revenue from gold or silver mining, or at least 50% of their mining mineral resources are from gold or silver. For more information about the MVIS® Global Junior Gold Miners Index, please visit the index provider’s website.

1Source: https://www.marketvector.com/indexes/hard-asset/mvis-global-junior-gold-miners

About TRX Gold Corporation

TRX Gold is a high margin and growing gold company advancing the Buckreef Gold Project in Tanzania. Buckreef Gold includes an established open pit operation and 2,000 tonnes per day process plant with upside potential demonstrated in the May 2025 Preliminary Economic Assessment (the “PEA”). The PEA outlines average gold production of 62,000 oz per annum over 17.6 years at 3,000 tonnes per day of throughput capacity, and a US$1.9 –US$2.6 billion pre-tax NPV5% at average life of mine gold prices of US$4,000-US$5,000/oz. The Buckreef Gold Project hosts a Measured and Indicated Mineral Resource of 10.8 million tonnes (“MT”) at 2.57 grams per tonne (“g/t”) gold containing 893,000 ounces (“oz”) of gold and an Inferred Mineral Resource of 9.1 MT at 2.47 g/t gold for 726,000 oz of gold. The leadership team is focused on creating both near-term and long-term shareholder value by increasing gold production to generate positive cash flow to fund the expansion as outlined in the PEA and grow Mineral Resources through exploration. TRX Gold’s actions are led by the highest environmental, social and corporate governance (“ESG”) standards, evidenced by the relationships and programs that the Company has developed during its nearly two decades of presence in the Geita Region, Tanzania.

Qualified Person

Mr. Richard Boffey, BE Mining (Hons) F AusIMM, Chief Operating Officer of TRX Gold Corporation, is the Company’s in-house Qualified Person under National Instrument 43-101 “Standards of Disclosure for Mineral Projects” (“NI 43-101”) and has reviewed and assumes responsibility for the scientific and technical content in this press release.

For investor or shareholder inquiries, please contact:

Investor Relations
IR@TRXgold.com
+1-437-224-5241
+1 844 GOLD TRX (844-465-3879)
www.TRXgold.com

Forward-Looking and Cautionary Statements

This press release contains certain forward-looking statements as defined in the applicable securities laws. All statements, other than statements of historical facts, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “hopes”, “intends”, “estimated”, “potential”, “possible” and similar expressions, or statements that events, conditions or results “will”, “may”, “could” or “should” occur or be achieved. Forward-looking statements relate to future events or future performance and reflect TRX Gold management’s expectations or beliefs regarding future events and include, but are not limited to, statements with respect to future inclusion of TRX Gold in additional indices or funds, ability to attract investors or increase liquidity as a result of being included in any index or for any other reason, future gold prices, continued operating cash flow, expansion of its process plant, estimation of mineral resources, ability to develop value creating activities, recoveries, subsequent project testing, success, scope and viability of mining operations, the timing and amount of estimated future production and capital expenditures.

Although TRX Gold believes the expectations expressed in such forward-looking statements and the preliminary data included in this press release are based on reasonable assumptions, such statements are not guarantees of future performance. The actual achievements of TRX Gold or other future events or conditions may differ materially from those reflected in the preliminary data and forward-looking statements due to a variety of risks, uncertainties and other factors. These risks, uncertainties and factors include general business, legal, economic, competitive, political, regulatory and social uncertainties; actual results from operations, exploration activities and economic evaluations; fluctuations in currency exchange rates; changes in costs; future prices of gold and other minerals; mining method, production profile and mine plan; delays in exploration, development and construction activities; changes in government legislation and regulation; the ability to obtain financing on acceptable terms and in a timely manner or at all; contests over title to properties; employee relations and shortages of skilled personnel and contractors; the speculative nature of, and the risks involved in, the exploration, development and mining business. These risks are set forth in reports that TRX Gold files with the SEC and the various Canadian securities authorities. You can review and obtain copies of these filings from the SEC’s website at http://www.sec.gov/edgar.shtml and the Company’s profile on the System for Electronic Document Analysis and Retrieval (“SEDAR+”) at www.sedarplus.ca.

The disclosure contained in this press release of a scientific or technical nature relating to the Company’s Buckreef Project has been summarized or extracted from the technical report prepared in accordance with NI 43-101 – Standards of Disclosure for Mineral Projects on the Buckreef Gold Project (“Buckreef Gold”) titled Preliminary Economic Assessment and Updated Mineral Resource Estimate of the Buckreef Gold Mine Project, Tanzania (“PEA”) with an effective date of April 15, 2025. The PEA was prepared in accordance with NI 43-101 guidelines by P&E Mining Consultants Inc. (“P&E”). Input to this PEA was also provided by D.E.N.M. Engineering Ltd. (“D.E.N.M.”). The information contained herein is subject to all of the assumptions, qualifications and procedures set out in, and is qualified in its entirety by reference to the full text of, the PEA and reference should be made to the full details of the PEA which has been filed with the applicable regulatory authorities and is available on the Company’s profile at www.sedarplus.ca.

The information contained in this press release is as of the date of the press release and TRX Gold assumes no duty to update such information.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.